Azitra, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Azitra announced October 1, 2026 that its Phase 1/2 clinical trial of ATR-04 (a live biotherapeutic for EGFR inhibitor-associated skin rash) completed Cohort 1 with 7 patients and received safety review committee clearance to proceed to Cohort 2, expecting ~24 patients. The trial is a randomized, double-blind, vehicle-controlled study across 6 sites including MD Anderson and Yale. No safety concerns were reported that would halt progression.
Why this rating
Moderate milestone for micro-cap: trial progression validates lead asset but company is clinical-stage; safety data still limited (6 patients reviewed). Material relative to $4.7M market cap, but binary clinical risk remains.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.